Publicidad
Idiomas disponibles
Idiomas disponibles
Intended purpose
®
The eBase
Controller is used to operate
®
eFlow
Technology nebuliser handsets,
®
e.g., Tolero
for Vantobra
®
eFlow
rapid for Colfinair
handset is not included in this kit, and is
made available for use with a specially
approved drug and/or via a specific distri-
bution channel.
Indication
®
The eBase
Controller has no indication.
Intended use
®
The eBase
Controller must only be
operated in accordance with its intended
purpose.
WARNING:
For reasons of hygiene and to avoid
cross-infections, the nebuliser system (the
®
eBase
Controller in conjunction with a
nebuliser handset) must only be used by
one patient.
WARNING:
Do not use any other drug than the one
approved for the nebuliser handset.
CAUTION:
Never attempt to inhale essential oils, as
this can cause irritation of the airways
(intense coughing).
8
®
and
®
. The nebuliser
Only original PARI accessories must be
used to operate the system.
CAUTION:
Using accessories and spare parts other
than those supplied by the manufacturer
may cause increased electromagnetic
emissions or reduced electromagnetic
immunity, leading to a malfunction.
PARI Pharma GmbH is not responsible
for damage if the system is used improp-
erly or contrary to the instructions.
Contraindications
®
The eBase
Controller has no
contraindication.
Intended patient groups
The nebuliser system guarantees highly
effective, fast inhalation treatment for
patients aged from infant to adult. The
exact age at which treatment can start
depends on the drug and may vary from
one drug to another.
The nebuliser system is only suitable for
use by patients who can breathe
unassisted and are conscious.
Info:
Besides the information in these
instructions for use, please also take
note of the package inserts for the
nebuliser handset and the
medication.
Lifetime of the medical
device
- The expected life time of the
®
eBase
Controller is 3 years.
- Nebuliser handset: Follow the instruc-
tions for use of the nebuliser handset
you are using.
eBase
®
Controller - 2022-09
Publicidad
